CERENOME, INC.
Tremor tracks 2 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
None right now.
Trials
- CNSYCerenome0Calm
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Running, no new patientsPhase 1/255 patientsMain results: Apr 2027 - CNSYCerenome0Calm
Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases
Signing up patientsPhase 1/224 patientsMain results: Jul 31, 2027
Key executives leaving
From the last 12 months of the company's SEC reports.
None found.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
0 sales (0 not pre-planned) · 0 purchases
No insider sales or purchases in the last 6 months.
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
Money left
Coming soon: how many months of cash the company has, from its quarterly reports.